Provectus Biopharmaceuticals, Inc. PVCT
Set alert
0.05 USD 0.00 -4.00%
At close · Oct 30
0.048 Day range 0.048
0.038 52-week range 0.077
- YTD
- -14.29%
- 1 year
- -33.33%
- Open
- 0.048
- Prev close
- 0.05
- Mkt cap
- 20.17M
- Vol
- 20.50K
- Avg vol
- 112.53K
- EPS
- -0.01
- P/E
- 0.00
More statistics
- Low
- 0.048
- High
- 0.048
1M chart
Signals (9)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 29, 2026 | 4 days ago |
| RSI: Oversold | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 14, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 12, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
Financials — quick view
PVCT Revenue — quarterly 161.84K
PVCT Net income — quarterly -835.06K
PVCT EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | 0.00 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | 0.00 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | 0.00 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | 0.00 | — | — |
News
- VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase
- Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose
- Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
- Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
- Provectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call Transcript
- Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders
- Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
- Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
- Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
- Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
Your note
Sign in to keep a note on PVCT — it syncs with the Stock Master app.